Article
BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Hong Kong medical journal = Xianggang yi xue za zhi - 1 Oct 2009
Kwan T K, Ma Edmond S K, Chan Y Y, Wan Thomas S K, Liu Herman S Y, Sim Joycelyn P Y, Yeung Y M, Lie Albert K W, Yip S F
Abstract excerpt
Imatinib is the standard treatment for chronic myeloid leukaemia. BCR-ABL kinase domain mutation is the commonest mechanism implicated in imatinib resistance. In in-vitro studies, kinase domain mutations are variably resistant to second-line agents. We performed BCR-ABL kinase domain mutational studies in 25 patients in five institutions who failed imatinib and were treated with either nilotinib or dasatinib, to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.